[
  {
    "ts": null,
    "headline": "Pfizer Earnings Preview: What to Expect",
    "summary": "Pfizer is expected to announce its second-quarter results next month, and analysts predict a single-digit drop in the company’s bottom-line figure.",
    "url": "https://finnhub.io/api/news?id=3a097ab9eedd84735e42b93c448ff502448aa6586a2e74564e749f2c0e337fec",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752077538,
      "headline": "Pfizer Earnings Preview: What to Expect",
      "id": 135835971,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer is expected to announce its second-quarter results next month, and analysts predict a single-digit drop in the company’s bottom-line figure.",
      "url": "https://finnhub.io/api/news?id=3a097ab9eedd84735e42b93c448ff502448aa6586a2e74564e749f2c0e337fec"
    }
  },
  {
    "ts": null,
    "headline": "Cogent: Positive Data In NonAdvSM Bodes Well For 2nd Half AdvSM Treatment Results",
    "summary": "Cogent Biosciences, Inc. is a Strong Buy after trial data for bezuclastinib & market growth potential in systemic mastocytosis treatments! Click for my COGT update.",
    "url": "https://finnhub.io/api/news?id=77120f707c22504a65928b10b0e1be041b152d3faff9a250caeaf0987e5b65ae",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752077049,
      "headline": "Cogent: Positive Data In NonAdvSM Bodes Well For 2nd Half AdvSM Treatment Results",
      "id": 135838027,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1374014442/image_1374014442.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Cogent Biosciences, Inc. is a Strong Buy after trial data for bezuclastinib & market growth potential in systemic mastocytosis treatments! Click for my COGT update.",
      "url": "https://finnhub.io/api/news?id=77120f707c22504a65928b10b0e1be041b152d3faff9a250caeaf0987e5b65ae"
    }
  },
  {
    "ts": null,
    "headline": "Recent Agreements Set To Bolster BioNTech SE (BNTX)’s Oncology Arm",
    "summary": "BioNTech SE (NASDAQ:BNTX) is one of the 13 Best German Stocks to Invest in Now. It is a clinical-stage biotechnology company focused on immunotherapies to treat cancer and other serious diseases. On June 2, the company announced that it had agreed with Bristol Myers Squibb for the global joint development and commercialization of BioNTech SE (NASDAQ:BNTX)’s […]",
    "url": "https://finnhub.io/api/news?id=917a120659ae01061764c32121344d094ba81b04af88c6c8190b78a5e1642b33",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752071445,
      "headline": "Recent Agreements Set To Bolster BioNTech SE (BNTX)’s Oncology Arm",
      "id": 135835972,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "BioNTech SE (NASDAQ:BNTX) is one of the 13 Best German Stocks to Invest in Now. It is a clinical-stage biotechnology company focused on immunotherapies to treat cancer and other serious diseases. On June 2, the company announced that it had agreed with Bristol Myers Squibb for the global joint development and commercialization of BioNTech SE (NASDAQ:BNTX)’s […]",
      "url": "https://finnhub.io/api/news?id=917a120659ae01061764c32121344d094ba81b04af88c6c8190b78a5e1642b33"
    }
  },
  {
    "ts": null,
    "headline": "Major deals involving U.S. drugmakers and biotechs over the past decade",
    "summary": "Merck is acquiring UK-basedVerona Pharma for about $10 billion, as part of theU.S. drugmaker's strategy to diversify beyond its blockbustercancer treatment Keytruda. The move adds to a growing...",
    "url": "https://finnhub.io/api/news?id=8c72d70e6cd133c597c22d5733de9eb506e7df79fbc944267bd6e417cd41bc70",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752067782,
      "headline": "Major deals involving U.S. drugmakers and biotechs over the past decade",
      "id": 135835446,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Merck is acquiring UK-basedVerona Pharma for about $10 billion, as part of theU.S. drugmaker's strategy to diversify beyond its blockbustercancer treatment Keytruda. The move adds to a growing...",
      "url": "https://finnhub.io/api/news?id=8c72d70e6cd133c597c22d5733de9eb506e7df79fbc944267bd6e417cd41bc70"
    }
  },
  {
    "ts": null,
    "headline": "Merck Faces Multiple Challenges: Will It Steer Through Successfully?",
    "summary": "MRK banks on new launches as Keytruda faces a looming patent cliff and Gardasil weakens amid China's demand slump.",
    "url": "https://finnhub.io/api/news?id=3913d662aa4220ce980be59df562b1a9635337751fca0692b11b698b88d7d6f9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752067440,
      "headline": "Merck Faces Multiple Challenges: Will It Steer Through Successfully?",
      "id": 135835679,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "MRK banks on new launches as Keytruda faces a looming patent cliff and Gardasil weakens amid China's demand slump.",
      "url": "https://finnhub.io/api/news?id=3913d662aa4220ce980be59df562b1a9635337751fca0692b11b698b88d7d6f9"
    }
  },
  {
    "ts": null,
    "headline": "JNJ vs. Pfizer: Which Pharma Giant is the Better Investment Now?",
    "summary": "JNJ's growth outlook, rising estimates, and strength in Innovative Medicine give it an edge over Pfizer in 2025.",
    "url": "https://finnhub.io/api/news?id=a86b9dbd8b7aabe2229ea6c55ec1bfc8413de7c088bef9cd2a32c486de83df64",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752066660,
      "headline": "JNJ vs. Pfizer: Which Pharma Giant is the Better Investment Now?",
      "id": 135835727,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "JNJ's growth outlook, rising estimates, and strength in Innovative Medicine give it an edge over Pfizer in 2025.",
      "url": "https://finnhub.io/api/news?id=a86b9dbd8b7aabe2229ea6c55ec1bfc8413de7c088bef9cd2a32c486de83df64"
    }
  },
  {
    "ts": null,
    "headline": "Companies Like Pfizer Inc (PFE) are Boosting the Cannabis Light Market",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the 10 Best Non-Tech Stocks to Buy and Hold For 3 Years. On July 1, GlobalNewswire reported that the Cannabis Light Market is expected to grow at a Compound Annual Growth Rate (CAGR) of 7.6% from 2025 to 2030. This is because companies like Pfizer Inc. (NYSE:PFE) have entered the […]",
    "url": "https://finnhub.io/api/news?id=a41b2ad333b1c28c55cb3f15bd4d1260eeb09a06589a0dfef9a2aa29ebfa163e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752037404,
      "headline": "Companies Like Pfizer Inc (PFE) are Boosting the Cannabis Light Market",
      "id": 135829963,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is one of the 10 Best Non-Tech Stocks to Buy and Hold For 3 Years. On July 1, GlobalNewswire reported that the Cannabis Light Market is expected to grow at a Compound Annual Growth Rate (CAGR) of 7.6% from 2025 to 2030. This is because companies like Pfizer Inc. (NYSE:PFE) have entered the […]",
      "url": "https://finnhub.io/api/news?id=a41b2ad333b1c28c55cb3f15bd4d1260eeb09a06589a0dfef9a2aa29ebfa163e"
    }
  }
]